Intellectual property


International standards on intellectual property: click here

Get RSS feed of these results

Related stories and components

Article
19 June 2013

The Human Rights-Related Aspects of Indigenous Knowledge in the Context of Common Law Equitable Doctrines and Implications of the Kiobel Decision

Author: Lydie Pierre-Louis, David Orozco & Kevin J. McGarry

This article will examine the nexus between human rights; knowledge produced, maintained, and regulated by indigenous societies; and equitable principles inherent within private contract law. The issue of indigenous knowledge has generated significant...

Read more

Article
14 June 2013

Big pharma problem for HIV/AIDS [Uganda]

Author: Henry Zakumumpa, in The Independent (Uganda)

The lives of thousands of Ugandans enrolled on HIV treatment hang in the balance after an application by poor countries to extend the deadline for manufacture of generic AIDS drugs was rejected by the World Trade Organization (WTO)...Over 90% of HIV...

Read more

Article
13 June 2013

Supreme Court Gene Ruling Benefits Biotech, Breast Cancer Research [USA]

Author: Megan McGrath, Voice of America

Everyone has BRCA genes in their cells. If you are a woman and one of your BRCA gene copies has a mutation, your risk of developing breast cancer is very high - up to 87 percent in some cases…Myriad Genetics Inc. was the first to discover the healthy,...

Read more

Article
13 June 2013

UN Human Rights Council Adopts Resolution Promoting Medicines Access

Author: Intellectual Property Watch

The United Nations Human Rights Council today adopted a resolution urging governments to encourage technology development and transfer and to apply intellectual property rights measures in ways that avoid creating barriers to trade in “affordable,...

Read more

Article
14 May 2013

Patent wars: has India taken on Big Pharma and won?

Author: Tim Smedley, Guardian [UK]

On 1 April, pharma giant Novartis lost a six-year legal battle after the Indian supreme court ruled that small changes to its leukaemia drug Glivec did not deserve a new patent.…And only one month before, India upheld a compulsory licence of Bayer's...

Read more

Article
29 April 2013

5 Take-Home Points From India’s Historic Novartis Patent Case

Author: Arvind Subramanian, Asian Scientist (Singapore)

...[T]he Indian Supreme Court dismissed the attempt by Novartis...to obtain patent protection for...Glivec...The verdict follows the Indian Patent Office’s decision last month to grant an Indian drug manufacturer a compulsory licence to sell a generic...

Read more

Article
15 April 2013

Why Novartis case will help innovation [India]

Author: Achal Prabhala & Sudhir Krishnaswamy, in Hindu (India)

[T]he Supreme Court upheld the Intellectual Property Appellate Board’s decision to deny patent protection to Novartis’s application…[T]he…judgment effectively recast Indian patent law as being nuanced and original…[T]he global gold rush for patents...

Read more

Article
8 April 2013

India’s Patently Wise Decision

Author: Joseph E. Stiglitz & Arjun Jayadev, Project Syndicate

The Indian Supreme Court’s refusal to uphold the patent on Gleevec, the blockbuster cancer drug developed by the Swiss pharmaceutical giant Novartis, is good news for many of those in India suffering from cancer. If other developing countries follow...

Read more

Article
3 April 2013

Novartis Defeat Revives Debate Over Patents' Life Span [India]

Author: Lisa Shuchman, Corporate Counsel [USA]

When India's Supreme Court ruled this week that Novartis AG's cancer drug Gleevec was not sufficiently innovative to merit a patent, public health advocates lauded the decision, which they said would give more people access to needed drugs, and Big...

Read more

Article
1 April 2013
+ Français - Hide

Author: Julien Bouissou, Le Monde

C'est un nouveau coup dur pour l'industrie pharmaceutique en Inde, et une nouvelle étape vers un accès plus large des populations défavorisées aux médicaments génériques. En rejetant…la demande de brevet déposée par…Novartis sur le Glivec…la Cour...

Read more